What is Seroquel and should you take it for insomnia?

August 29, 2017 by Petra Czarniak, The Conversation
The evidence so far suggests off-label prescribing for insomnia places users at unnecessary risk of harm. Credit: Flavio Ronco/Flickr, CC BY-NC-ND

Quetiapine, sold under the brand name Seroquel, is a short-acting antipsychotic drug. It's used to treat schizophrenia, bipolar I disorder and as an add-on treatment for major depression and generalised anxiety disorder in people who haven't responded to other therapies. The recommended dose range for these conditions is 200-800mg a day.

Off-label prescribing is when a is prescribed for uses outside those for which it has been licensed. It's relatively common in psychiatry and may help patients who haven't responded to standard treatments. But due to the lack of evidence for the safety and efficacy of off-label uses, there is a potential for harm.

Doctors prescribe quetiapine off-label for various conditions, including anxiety, autism, , substance abuse and . It is also increasingly prescribed off-label for insomnia, usually at lower doses of 100mg or less a day.

But the evidence so far suggests the risks of prescribing quetiapine off-label outweigh any benefits.

Rise in use

Since quetiapine came onto the market in 1997, prescription rates have skyrocketed, especially in the United States, where it became the fifth-biggest-selling pharmaceutical in 2010.

Prescriptions for quetiapine also increased significantly in Australia between 2000 and 2011.

Patients switching from another antipsychotic to quetiapine cannot account for these changes; the rise is most likely due to off-label prescribing.

In fact, drug company AstraZeneca paid US$520 million in 2010 to resolve allegations the company illegally marketed Seroquel for uses not approved by the US Food and Drug Administration (FDA).

Antipsychotic drugs

All – both first generation, which were developed in the 1950s, and second generation, developed since the 1950s – exert their effect mainly by blocking dopamine transmission in various parts of the brain. They block dopamine D2 receptors, which alleviates symptoms of psychosis such as hallucinations, delusions and thought disorder.

Other receptors may also be blocked. However, these blockages may cause serious side effects.

Quetiapine is sold under the brand name Seroquel. Credit: hopeless128/Flickr, CC BY-NC-ND

Quetiapine is a second-generation antipsychotic drug that also blocks histamine H1 and serotonin type 2A receptors. This is thought to account for its sedative properties, which is why it's used off-label for insomnia.

Antipsychotic drugs, especially first-generation antipsychotics such as haloperidol, fluphenazine and trifluoperazine, can be associated with some serious side effects, such as the neurological disorder tardive dyskinesia. This involves involuntary movements of the face, tongue and mouth and, less commonly, the limbs, head, neck and trunk. In some cases, tardive dyskinesia may be irreversible.

All antipsychotic drugs can also cause neuroleptic malignant syndrome, a which can progress rapidly over 24 to 72 hours. Neuroleptic malignant syndrome can cause instability, altered consciousness, muscle rigidity and even death. The incidence is greatest in young men.

Both first- and second-generation antipsychotics have been reported to contribute to heart arrhythmia, where the electrical impluses co-ordinating your heartbeats malfunction. In a recent large cohort study, researchers reported that antipsychotic drugs, including quetiapine, almost doubled the risk of sudden death from a heart attack.

Quetiapine has fewer side effects than first-generation antipsychotics. But recent research and clinical trials have reported considerable risk of metabolic side effects. These include weight gain, elevation of cholesterol and triglycerides, and diabetes, even when prescribed at recommended doses.

Quetiapine as a sleeping drug

Studies on the use of quetiapine for sedation have produced conflicting results.

A very small randomised placebo-controlled study, funded by AstraZeneca (manufacturer of quetiapine) and involving 14 healthy subjects, reported that, compared to placebo, both 25mg and 100mg quetiapine administered at night increased the sleep quality and the amount of sleep.

Another independent study conducted in Thailand did not support these findings. Researchers tested the drug in a randomised two-week controlled trial (where one group received the drug and another received a placebo). They found 25mg quetiapine at night for primary insomnia did not improve sleep.

Quetiapine can cause significant , even when used in small to moderate doses for sleep. It has also been associated with increased blood glucose (sugar) and dyslipidaemia (an imbalance of fats circulating in the blood). These increase the risk of developing type 2 diabetes and heart disease.

In a retrospective study in the United Kingdom, 43 psychiatric patients aged 19 to 65 years were prescribed low-dose quetiapine for insomnia, usually 100mg at bedtime. Over the 11-month study period, their weight increased by an average of 2.22kg.

Despite the safety concerns associated with using quetiapine as an antipsychotic, the risks may be acceptable when treating patients with serious mental illness, given there are few alternatives.

But the evidence so far suggests prescribing off-label for people who have problems sleeping places them at unnecessary risk of harm.

Explore further: Unusual combo reduces health risk from atypical antipsychotic

Related Stories

Unusual combo reduces health risk from atypical antipsychotic

June 2, 2016
Atypical antipsychotics, though effective for treating disorders like schizophrenia, bipolar disorder, and depression, gives patients a heightened risk of developing new-onset diabetes. A new data mining study, however, has ...

A comparison between quetiapine and aripiprazole for treatment of schizophrenia

July 13, 2016
Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing problems with recurrent psychotic ...

Less than half of UK prescriptions for antipsychotics issued for main licensed conditions

December 18, 2014
Less than half of UK prescriptions for antipsychotic drugs are being issued to treat the serious mental illnesses for which they are mainly licensed, reveals research published in the online journal BMJ Open.

Problems continue with inappropriate prescription of antipsychotic drugs

November 7, 2013
Low-dose, antipsychotic medications are continuing to be widely prescribed, a new analysis suggests, even though it's likely many of the prescriptions are for conditions where there's weak evidence of their effectiveness ...

Atypical antipsychotics may aid symptons for some off-label uses, but not others

September 27, 2011
Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study.

Antipsychotic drugs linked to increased mortality among Parkinson's disease patients

March 21, 2016
At least half of Parkinson's disease patients experience psychosis at some point during the course of their illness, and physicians commonly prescribe antipsychotic drugs, such as quetiapine, to treat the condition. However, ...

Recommended for you

A walk at the mall or the park? New study shows, for moms and daughters, a walk in the park is best

November 17, 2017
Spending time together with family may help strengthen the family bond, but new research from the University of Illinois shows that specifically spending time outside in nature—even just a 20-minute walk—together can ...

When male voles drink alcohol, but their partner doesn't, their relationship suffers

November 17, 2017
A study of the effect of alcohol on long-term relationships finds that when a male prairie vole has access to alcohol, but his female partner doesn't, the relationship suffers - similar to what has been observed in human ...

Risk of distracted driving predicted by age, gender, personality and driving frequency

November 17, 2017
New research identifies age, gender, personality and how often people drive as potential risk factors for becoming distracted while driving. Young men, extroverted or neurotic people, and people who drive more often were ...

Spanking linked to increase in children's behavior problems

November 16, 2017
Children who have been spanked by their parents by age 5 show an increase in behavior problems at age 6 and age 8 relative to children who have never been spanked, according to new findings in Psychological Science, a journal ...

Generous people give in a heartbeat—new study

November 15, 2017
Altruistic people are said to be "kind hearted" - and new research published in the journal Scientific Reports shows that generous people really are more in touch with their own hearts.

Teenage depression linked to father's depression

November 15, 2017
Adolescents whose fathers have depressive symptoms are more likely to experience symptoms of depression themselves, finds a new study led by UCL researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.